{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:11:55Z","timestamp":1761491515671,"version":"build-2065373602"},"reference-count":61,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Allogeneic stem cell transplantation (allo-SCT) represented the first immunotherapy to treat hematologic malignancies: it has been considered as a cure for the disease and never as an approach to extend the life of patients. The success of allo-SCT derives both from the ability to treat patients with intensive chemoradiotherapy and from the potent graft-versus-leukemia effects mediated by donor immunity. Although considerable progress has been made in the last years, significant barriers still remain in the form of disease relapse, graft-versus-host disease, infectious complications, and regimen-related toxicities. Moreover, the treatment of hematologic malignancies, particularly acute lymphoblastic leukemia and certain forms of lymphomas, has been revolutionized by the commercial introduction of genetically modified autologous T-lymphocyte therapy (CAR-T). Our review discusses current standards and the shifting paradigms in the indications for allo-SCT and the role of CAR-T cell therapy for lymphoid neoplasms.<\/jats:p>","DOI":"10.3390\/ijms24021045","type":"journal-article","created":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T01:48:19Z","timestamp":1672969699000},"page":"1045","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Do CAR-T and Allogeneic Stem Cell Transplant Both Have a Place in Lymphoid Neoplasms?"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3987-419X","authenticated-orcid":false,"given":"Massimo","family":"Martino","sequence":"first","affiliation":[{"name":"Stem Cell Transplant and Cellular Therapies Unit, Great Metropolitan Hospital \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC 587, Great Metropolitan Hospital \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo Antonio","family":"Canale","sequence":"additional","affiliation":[{"name":"Stem Cell Transplant and Cellular Therapies Unit, Great Metropolitan Hospital \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC 587, Great Metropolitan Hospital \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Naso","sequence":"additional","affiliation":[{"name":"Stem Cell Transplant and Cellular Therapies Unit, Great Metropolitan Hospital \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC 587, Great Metropolitan Hospital \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetana","family":"Porto","sequence":"additional","affiliation":[{"name":"Stem Cell Transplant and Cellular Therapies Unit, Great Metropolitan Hospital \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC 587, Great Metropolitan Hospital \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Demetrio","family":"Gerace","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Human Pathology in Adulthood and Childhood \u201cGaetano Barresi\u201d, University of Messina, 98125 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6156-8239","authenticated-orcid":false,"given":"Alessandro","family":"Allegra","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Human Pathology in Adulthood and Childhood \u201cGaetano Barresi\u201d, University of Messina, 98125 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"6445","DOI":"10.1158\/0008-5472.CAN-16-1311","article-title":"Allogeneic Stem Cell Transplantation: A Historical and Scientific Overview","volume":"76","author":"Singh","year":"2016","journal-title":"Cancer Res."},{"key":"ref_2","first-page":"112","article-title":"Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning","volume":"54","author":"Petersen","year":"2007","journal-title":"Dan. Med. Bull."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.humimm.2022.08.007","article-title":"Current donor selection strategies for allogeneic hematopoietic cell transplantation","volume":"83","author":"Timofeeva","year":"2022","journal-title":"Hum. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1005042","DOI":"10.3389\/fonc.2022.1005042","article-title":"Outcomes with mismatched unrelated donor allogeneic hematopoietic stem cell transplantation in adults: A systematic review and meta-analysis","volume":"12","author":"Mushtaq","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/s41409-022-01604-x","article-title":"Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: A report from the EBMT activity survey","volume":"57","author":"Passweg","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"ref_6","unstructured":"FDA (2018, March 05). Approves Tisagenlecleucel for Adults with Relapsed or Refractory Large B-Cell Lymphoma, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tisagenlecleucel-adults-relapsed-or-refractory-large-b-cell-lymphoma."},{"key":"ref_7","unstructured":"FDA (2022, August 09). Approves Axicabtagene Ciloleucel for Large B-Cell Lymphoma, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-axicabtagene-ciloleucel-large-b-cell-lymphoma."},{"key":"ref_8","unstructured":"(2022, August 09). First Two CAR-T Cell Medicines Recommended for Approval in the European Union. Available online: https:\/\/www.ema.europa.eu\/en\/news\/first-two-car-t-cell-medicines-recommended-approval-european-union."},{"key":"ref_9","unstructured":"FDA (2022, August 09). Approves Lisocabtagene Maraleucel for Relapsed or Refractory Large B-Cell Lymphoma, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-lisocabtagene-maraleucel-relapsed-or-refractory-large-b-cell-lymphoma."},{"key":"ref_10","unstructured":"FDA (2022, August 09). Approves Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-mantle-cell-lymphoma."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"7002","DOI":"10.1200\/JCO.2021.39.15_suppl.7002","article-title":"Phase 2 results of the ZUMA-3 study evaluating KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (pts) with relapsed\/refractory B-cell acute lymphoblastic leukemia (R\/R B-ALL)","volume":"39","author":"Shah","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_12","unstructured":"FDA (2022, August 09). Approves Idecabtagene Vicleucel for Multiple Myeloma, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-idecabtagene-vicleucel-multiple-myeloma."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Martino, M., Alati, C., Canale, F.A., Musuraca, G., Martinelli, G., and Cerchione, C. (2021). A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22042150"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Martino, M., Naso, V., Loteta, B., Canale, F.A., Pugliese, M., Alati, C., Musuraca, G., Nappi, D., Gaimari, A., and Nicolini, F. (2022). Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232113332"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","article-title":"European Society for Blood and Marrow Transplantation (EBMT). Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: Current practice in Europe, 2022","volume":"57","author":"Snowden","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1200\/JCO.2010.30.2596","article-title":"Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin\u2019s lymphoma relapsing after an autologous stem-cell transplantation: An analysis of the European Group for Blood and Marrow Transplantation Registry","volume":"29","author":"Canals","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(14)70161-5","article-title":"German High-Grade Lymphoma Study Group. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): An open-label, randomised, phase 2 trial","volume":"15","author":"Glass","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.bbmt.2017.03.031","article-title":"Allogeneic Stem Cell Transplantation for Relapsed\/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen","volume":"23","author":"Dodero","year":"2017","journal-title":"Biol. Blood Marrow Transplant"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/bjh.14046","article-title":"Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation","volume":"174","author":"Fenske","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of- care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: Results from the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1182\/blood-2021-148039","article-title":"Primary analysis of ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard-of-care therapy in patients with relapsed\/refractory large B-cell lym- phoma","volume":"138","author":"Locke","year":"2021","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1182\/blood-2021-147913","article-title":"Lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, versus standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (Pts) with relapsed or refractory (R\/R) large B-cell lymphoma (LBCL): Results from the randomized phase 3 transform study","volume":"138","author":"Kamdar","year":"2021","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"20406207221103321","DOI":"10.1177\/20406207221103321","article-title":"Current options and future perspectives in the treatment of patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"13","author":"Frontzek","year":"2022","journal-title":"Ther. Adv. Hematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1182\/bloodadvances.2021005788","article-title":"Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: A noncomparative cohort analysis","volume":"6","author":"Hamadani","year":"2022","journal-title":"Blood Adv."},{"key":"ref_29","first-page":"1","article-title":"Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma","volume":"18","author":"Zurko","year":"2022","journal-title":"Haematologica"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Fried, S., Shouval, R., Walji, M., Flynn, J.R., Yerushalmi, R., Shem-Tov, N., Danylesko, I., Tomas, A.A., Fein, J.A., and Devlin, S.M. (Transplant. Cell. Ther., 2022). Allogeneic Hematopoietic Cell Transplantation After CAR T-cell Therapy in Large B-cell Lymphoma: Allogeneic-HCT after CAR T-cell therapy, Transplant. Cell. Ther., in press.","DOI":"10.1016\/j.jtct.2022.10.026"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s11864-021-00906-4","article-title":"How to Sequence Therapies in Diffuse Large B-Cell Lymphoma Post-CAR-T Cell Failure","volume":"22","author":"Logue","year":"2021","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1182\/bloodadvances.2020002118","article-title":"Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies","volume":"4","author":"Sermer","year":"2020","journal-title":"Blood Adv."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Harmanen, M., Hujo, M., Sund, R., Sorigue, M., Khan, M., Prusila, R., Klaavuniemi, T., Kari, E., Jantunen, E., and Sunela, K. (2022). Survival of patients with mantle cell lymphoma in the rituximab era: Retrospective binational analysis between 2000 and 2020. Br. J. Haematol.","DOI":"10.1111\/bjh.18597"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lym- phoma: An international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1182\/hematology.2022000333","article-title":"What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma?","volume":"2022","author":"Kumar","year":"2022","journal-title":"Hematol. Am. Soc. Hematol. Educ. Progrom"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Post-ibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.2013.49.2454","article-title":"Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: Analysis of transplantation timing and modality","volume":"32","author":"Fenske","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Medical Research Council of the United Kingdom Adult ALL Working Party; Eastern Cooperative Oncology Group. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1470-2045(11)70386-2","article-title":"Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: A phase 2 study","volume":"13","author":"Kantarjian","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/bloodadvances.2019001381","article-title":"Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab","volume":"4","author":"Badar","year":"2020","journal-title":"Blood Adv."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"E201","DOI":"10.1002\/ajh.26526","article-title":"Dismal outcomes of patients with relapsed\/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab","volume":"97","author":"Short","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE- X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: Phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1038\/s41375-019-0615-5","article-title":"CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: Current status and perspectives","volume":"33","author":"Mohty","year":"2019","journal-title":"Leukemia"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/bloodadvances.2020001466","article-title":"Efficacy and safety of anti- CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leu- kemia with high-risk features","volume":"4","author":"Zhang","year":"2020","journal-title":"Blood Adv."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jtct.2021.10.003","article-title":"Hematopoietic Cell Transplantation after CD19 Chimeric Antigen Receptor T Cell-Induced Acute Lymphoblastic Lymphoma Remission Confers a Leukemia-Free Survival Advantage","volume":"28","author":"Summers","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.bbmt.2017.12.018","article-title":"Chimeric antigen receptor T-cell therapy can render patients with ALL into PCR-negative remission and can be an effective bridge to transplant","volume":"24","author":"Shalabi","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1182\/blood-2021-148652","article-title":"Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) As Consolidation Following CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for Treatment of Relapsed Acute Lymphoblastic Leukemia (ALL)","volume":"138","author":"Park","year":"2021","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s12032-018-1204-6","article-title":"Effect of transplant status in CD19-targeted CAR T-cell therapy: A systematic review and meta-analysis","volume":"35","author":"Nagle","year":"2018","journal-title":"Med. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"608916","DOI":"10.3389\/fonc.2020.608916","article-title":"Hematopoeitic Cell Transplantation and CAR T-Cell Therapy: Complements or Competitors?","volume":"10","author":"Goldsmith","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"784024","DOI":"10.3389\/fped.2021.784024","article-title":"Chimeric Antigen Receptor T-Cell Therapy in Paediatric B-Cell Precursor Acute Lymphoblastic Leukaemia: Curative Treatment Option or Bridge to Transplant?","volume":"9","author":"Buechner","year":"2022","journal-title":"Front. Pediatr."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jtct.2021.12.002","article-title":"Should CD19 CAR-T Cells for ALL be Followed by Allogeneic Stem Cell Transplant?","volume":"28","author":"Ramos","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.19.01892","article-title":"Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjh.17544","article-title":"Graft-versus-host disease risk after chimeric antigen receptor T-cell therapy: The diametric opposition of T cells","volume":"195","author":"Sanber","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","article-title":"Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: Results of two phase 1 studies","volume":"396","author":"Benjamin","year":"2020","journal-title":"Lancet"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-shelf\u2019 allogeneic CAR T cells: Development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1182\/blood-2017-08-752121","article-title":"Posttransplant chimeric antigen receptor therapy","volume":"131","author":"Smith","year":"2018","journal-title":"Blood"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/2\/1045\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:00:18Z","timestamp":1760119218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/2\/1045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,5]]},"references-count":61,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["ijms24021045"],"URL":"https:\/\/doi.org\/10.3390\/ijms24021045","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2023,1,5]]}}}